Bemarituzumab
- Generic Name
- Bemarituzumab
- Drug Type
- Biotech
- CAS Number
- 1952272-74-0
- Unique Ingredient Identifier
- RJW23BQ0KW
- Background
Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Target Recruit Count
- 27
- Registration Number
- NCT06978062
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6
- Registration Number
- NCT05913115
- Locations
- ๐ฏ๐ต
St Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan
๐ฏ๐ตNational Cancer Center Hospital, Chuo-ku, Tokyo, Japan
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 260
- Registration Number
- NCT05325866
- Locations
- ๐ฆ๐น
Landeskrankenhaus Salzburg, Salzburg, Austria
๐ซ๐ทGustave Roussy, Villejuif, France
๐จ๐ญKantonsspital Graubuenden, Chur, Switzerland
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
- Conditions
- Gastroesophageal Junction CancerGastric Cancer
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT05322577
- Locations
- ๐บ๐ธ
Northport Veterans Affairs Medical Center, Northport, New York, United States
๐ฏ๐ตFujita Health University Hospital, Toyoake-shi, Aichi, Japan
๐ฏ๐ตHirosaki University Hospital, Hirosaki-shi, Aomori, Japan
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
- Conditions
- Squamous-Cell Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT05267470
- Locations
- ๐จ๐ณ
Taipei Veterans General Hospital, Taipei, Taiwan
๐จ๐ณLinkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Taiwan
๐บ๐ธMontefiore Einstein Center for Cancer Care, Bronx, New York, United States
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Conditions
- Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 507
- Registration Number
- NCT05111626
- Locations
- ๐บ๐ธ
Greater Baltimore Medical Center, Baltimore, Maryland, United States
๐บ๐ธUniversity of Illinois Chicago, Chicago, Illinois, United States
๐บ๐ธProvidence Portland Medical Center, Portland, Oregon, United States
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Conditions
- Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 547
- Registration Number
- NCT05052801
- Locations
- ๐ฌ๐ท
251 General Airforce Hospital, Athens, Greece
๐ฌ๐ทGeneral Hospital of Athens Laiko, Athens, Greece
๐ฌ๐ทEvgenidio Hospital I Agia Trias, Athens, Greece
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
- Conditions
- Recurrent Bladder Cancer
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Registration Number
- NCT03801278
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
- Conditions
- Transitional Cell Carcinoma of the BladderGastric CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT02318329
- Locations
- ๐บ๐ธ
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
๐บ๐ธThe University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- Conditions
- Adenocarcinoma
- Interventions
- Drug: Standard cytotherapy
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 80
- Registration Number
- NCT02213289
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.